Literature DB >> 25662931

Regulation of the ITGA2 gene by epigenetic mechanisms in prostate cancer.

Suyin Paulynn Chin1, James R Marthick, Alison C West, Annabel K Short, Jyoti Chuckowree, Andrea M Polanowski, Russell J Thomson, Adele F Holloway, Joanne L Dickinson.   

Abstract

BACKGROUND: Integrin alpha2 beta1 (α2 β1 ) plays an integral role in tumour cell invasion, metastasis and angiogenesis, and altered expression of the receptor has been linked to tumour prognosis in several solid tumours. However, the relationship is complex, with both increased and decreased expression associated with different stages of tumour metastases in several tumour types. The ITGA2 gene, which codes for the α2 subunit, was examined to investigate whether a large CpG island associated with its promoter region is involved in the differential expression of ITGA2 observed in prostate cancer.
METHODS: Bisulphite sequencing of the ITGA2 promoter was used to assess methylation in formalin-fixed paraffin-embedded (FFPE) prostate tumour specimens and prostate cancer cell lines, PC3, 22Rv1 and LNCaP. Changes in ITGA2 mRNA expression were measured using quantitative PCR. ITGA2 functionality was interrogated using cell migration scratch assays and siRNA knockdown experiments.
RESULTS: Bisulphite sequencing revealed strikingly decreased methylation at key CpG sites within the promoter of tumour samples, when compared with normal prostate tissue. Altered methylation of this CpG island is also associated with differences in expression in the non-invasive LNCaP, and the highly metastatic PC3 and 22Rv1 prostate cancer cell lines. Further bisulphite sequencing confirmed that selected CpGs were highly methylated in LNCaP cells, whilst only low levels of methylation were observed in PC3 and 22Rv1 cells, correlating with ITGA2 transcript levels. Examination of the increased expression of ITGA2 was shown to influence migratory potential via scratch assay in PC3, 22Rv1 and LNCaP cells, and was confirmed by siRNA knockdown experiments.
CONCLUSIONS: Taken together, our data supports the assertion that epigenetic modification of the ITGA2 promoter is a mechanism by which ITGA2 expression is regulated.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  DNA methylation; epigenetics; integrins; prostate

Mesh:

Substances:

Year:  2015        PMID: 25662931     DOI: 10.1002/pros.22954

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  Is Integrin Subunit Alpha 2 Expression a Prognostic Factor for Liver Carcinoma? A Validation Experiment Based on Bioinformatics Analysis.

Authors:  Liang Zhang; Yi Huang; JunJun Ling; Wenlei Zhuo; Zhen Yu; Yunbo Luo; Yi Zhu
Journal:  Pathol Oncol Res       Date:  2018-12-04       Impact factor: 3.201

2.  A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer.

Authors:  Adele F Holloway; Joanne L Dickinson; Tristan Joseph Verhoeff
Journal:  Breast Cancer Res Treat       Date:  2022-01-31       Impact factor: 4.872

3.  Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease.

Authors:  Maria M Simile; Gavinella Latte; Maria I Demartis; Stefania Brozzetti; Diego F Calvisi; Alberto Porcu; Claudio F Feo; Maria A Seddaiu; Lucia Daino; Carmen Berasain; Maria L Tomasi; Matias A Avila; Francesco Feo; Rosa M Pascale
Journal:  Oncotarget       Date:  2016-08-02

4.  High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis.

Authors:  Tianxiao Xu; Meng Ma; Zhihong Chi; Lu Si; Xinan Sheng; Chuanliang Cui; Jie Dai; Sifan Yu; Junya Yan; Huan Yu; Xiaowen Wu; Huan Tang; Jiayi Yu; Yan Kong; Jun Guo
Journal:  Cancer Sci       Date:  2018-05-11       Impact factor: 6.716

5.  Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: new emerging cancer players.

Authors:  Sara Franceschi; Francesca Lessi; Paolo Aretini; Valerio Ortenzi; Cristian Scatena; Michele Menicagli; Marco La Ferla; Prospero Civita; Katia Zavaglia; Claudia Scopelliti; Alessandro Apollo; Francesco Giovanni Carbone; Riccardo Vannozzi; Generoso Bevilacqua; Francesco Pasqualetti; Antonio Giuseppe Naccarato; Chiara Maria Mazzanti
Journal:  Oncotarget       Date:  2018-05-08

6.  Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.

Authors:  Dianyun Ren; Jingyuan Zhao; Yan Sun; Dan Li; Zibo Meng; Bo Wang; Ping Fan; Zhiqiang Liu; Xin Jin; Heshui Wu
Journal:  J Exp Clin Cancer Res       Date:  2019-12-09

7.  Expression and prognostic impact of CD49b in human lung cancer.

Authors:  Anna Tirilomi; Omar Elakad; Sha Yao; Yuchan Li; Marc Hinterthaner; Bernhard C Danner; Philipp Ströbel; Theodor Tirilomis; Hanibal Bohnenberger; Alexander von Hammerstein-Equord
Journal:  Medicine (Baltimore)       Date:  2022-02-11       Impact factor: 1.817

8.  Alpha2beta1 Integrin Polymorphism in Diffuse Astrocytoma Patients.

Authors:  Silvia A Teixeira; Regislaine V Burim; Mariano S Viapiano; Lucas T Bidinotto; Suely K Nagashi Marie; Suzana M Fleury Malheiros; Sueli M Oba-Shinjo; Augusto F Andrade; Carlos G Carlotti
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

9.  Epigenetic silencing of ITGA2 by MiR-373 promotes cell migration in breast cancer.

Authors:  Wen Ding; Xiao-Lu Fan; Xuan Xu; Jin-Zhou Huang; Song-Hui Xu; Qian Geng; Rong Li; De Chen; Guang-Rong Yan
Journal:  PLoS One       Date:  2015-08-10       Impact factor: 3.240

10.  Blockade of ITGA2 Induces Apoptosis and Inhibits Cell Migration in Gastric Cancer.

Authors:  Yu-Chang Chuang; Hsin-Yi Wu; Yu-Ling Lin; Shey-Cherng Tzou; Cheng-Hsun Chuang; Ting-Yan Jian; Pin-Rong Chen; Yuan-Ching Chang; Chi-Hsin Lin; Tse-Hung Huang; Chao-Ching Wang; Yi-Lin Chan; Kuang-Wen Liao
Journal:  Biol Proced Online       Date:  2018-05-01       Impact factor: 3.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.